Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis ChemomAb Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, has published a research article in JCI Insight that highlights the important role of CCL24 in primary sclerosing cholangitis (PSC). The article includes extensive data showing that Chemomab..
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative have provided an enrollment update for the (Z)-Endoxifen arm of the ongoing I-SPY 2 clinical trial. Six patients have been dosed with Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive i..
Ocuphire Pharma, Inc. presented clinical data on their drug APX3330 in a late-breaker session at the American Diabetes Association's Annual Conference. The data showed that APX3330 reduced the worsening of diabetic retinopathy after 24 weeks of treatment. This could potentially shift the treatment paradigm for diabetic retinopathy and broaden the prescriber base to include primary care and endoc..
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..
